Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2018 · 10-Q
Revenue$7.80M$7.80M+85.0% vs Q2 2017 Net Income-$8.05M-$8.05MN/M vs Q2 2017 EPS Diluted-$0.15-$0.15N/M vs Q2 2017 Gross Profit$3,846,000+70.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$6,548,000N/M Free Cash Flowderived-$7,661,000N/M Margins · derivedGross margin49.3%−4.4 pt vs Q2 2017
Operating margin-101.7%−37.3 pt vs Q2 2017
Net margin-103.2%−37.6 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 9, 2018 · 40 d after period end